All lobbying filings

KELLEY DRYE & WARREN LLP

KELLEY DRYE & WARREN LLP filed a Q3 report for LABORATORY CORPORATION OF AMERICA HOLDINGS on October 20, 2026, reporting $110,000 in lobbying income.

Lobbying for LABORATORY CORPORATION OF AMERICA HOLDINGS · Clinical laboratory

All filings by KELLEY DRYE & WARREN LLP · Everything LABORATORY CORPORATION OF AMERICA HOLDINGS has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$110,000

What the client paid this registrant for the period.

Client based in

North Carolina

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, H.R. 9393, the Lower Costs, More Transparency Act, and H.R. 9645, the Health Care Price Certainty for All Americans Act, provisions relating to lab test price transparency; Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Bills named in this filing 6

H.R. 5269
RESULTS Act
S. 2761
RESULTS Act
H.R. 5582
Patients Deserve Price Tags Act
S. 2355
Patients Deserve Price Tags Act
H.R. 9393
Lower Costs, More Transparency Act of 2026
H.R. 9645
Health Care Price Certainty for All Americans Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.